- Home
- FRA vs ALT Comparison
FRA vs ALT Comparison
Compare FRA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRA | ALT |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | FRA | ALT |
|---|---|---|
| Price | $10.95 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 139.2K | ★ 4.1M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.06% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $10.50 | $2.56 |
| 52 Week High | $13.41 | $6.44 |
Technical Indicators
Market Signals| Indicator | FRA | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 54.85 |
| Support Level | $10.73 | $2.65 |
| Resistance Level | $10.98 | $3.09 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 100.00 | 52.68 |
Price Performance
Historical ComparisonAbout FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.